BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34713867)

  • 21. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.
    Sasamoto N; Vitonis AF; Fichorova RN; Yamamoto HS; Terry KL; Cramer DW
    Cancer Causes Control; 2021 Mar; 32(3):299-309. PubMed ID: 33462738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer.
    Baskić D; Ristić P; Matić S; Banković D; Popović S; Arsenijević N
    Biomarkers; 2007; 12(6):657-67. PubMed ID: 17852076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel serum metabolome score for breast cancer diagnosis.
    Rashed R; Darwish H; Omran M; Belal A; Zahran F
    Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
    Yonemori K; Katsumata N; Noda A; Uno H; Yunokawa M; Nakano E; Kouno T; Shimizu C; Ando M; Tamura K; Takeuchi M; Fujiwara Y
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1199-206. PubMed ID: 18528707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
    Sandri MT; Salvatici M; Botteri E; Passerini R; Zorzino L; Rotmensz N; Luini A; Mauro C; Bagnardi V; Cassatella MC; Bottari F; Casadio C; Colleoni M
    Breast Cancer Res Treat; 2012 Feb; 132(1):317-26. PubMed ID: 22065291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
    Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
    Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
    Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
    Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
    Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
    Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
    Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
    Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour markers in rheumatoid arthritis-associated interstitial lung disease.
    Wang T; Zheng XJ; Ji YL; Liang ZA; Liang BM
    Clin Exp Rheumatol; 2016; 34(4):587-91. PubMed ID: 27213221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
    Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
    Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study.
    He J; Wang X; Xiao R; Zuo W; Zhang W; Yao H
    Medicine (Baltimore); 2021 Mar; 100(9):e24724. PubMed ID: 33655937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between cancer antigen 15.3 value and qualitative and semiquantitative parameters of positron emission tomography/computed tomography in breast cancer patients.
    Cervino AR; Saibene T; Michieletto S; Ghiotto C; Bozza F; Saladini G; Evangelista L
    Curr Radiopharm; 2014; 7(1):20-8. PubMed ID: 24836946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.